SEC Tracker
Get the app

Cullinan Therapeutics CGEM

Cullinan Therapeutics reported a $49.39 million net loss

Cullinan Therapeutics (CGEM) filed a 10-Q with the SEC on Nov 10, 2026, 7:09 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $49.39 million for the three months ended Sep 30, 2026
  2. Cash and equivalents of $88.26 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Cullinan Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

1 new risk factor

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$52.6M−$57.25M+8.1%
Operating cash flow−$43.08M−$38.22M−13%
Cash$88.26M$78.64M+12%
New risk factors (1)
  • We will no longer qualify as a "smaller reporting company" after December 31, 2026, and, as a result, following the expiration of the SEC's transition period, we may become subject to additional disclosure and compliance requirements. +2 more paragraphs

Data on this page was fetched . The filing on SEC.gov is the record.